BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferenci P. Viral hepatitis: cure of chronic hepatitis C--required length of follow-up? Nat Rev Gastroenterol Hepatol 2015;12:10-1. [PMID: 25421584 DOI: 10.1038/nrgastro.2014.198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Garbuglia AR, Visco-Comandini U, Lionetti R, Lapa D, Castiglione F, D'Offizi G, Taibi C, Montalbano M, Capobianchi MR, Paci P. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. PLoS One 2016;11:e0158989. [PMID: 27560794 DOI: 10.1371/journal.pone.0158989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Pathak N, Lai ML, Chen WY, Hsieh BW, Yu GY, Yang JM. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. BMC Bioinformatics 2017;18:548. [PMID: 29297305 DOI: 10.1186/s12859-017-1957-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]